These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 19850220)

  • 21. Loss of antibodies, but not of protection.
    Wenzel JJ; Jilg W
    Lancet Infect Dis; 2010 Nov; 10(11):738-9. PubMed ID: 21029981
    [No Abstract]   [Full Text] [Related]  

  • 22. [Persistence of immunity after hepatitis B vaccination].
    Madaliński K
    Przegl Epidemiol; 2002; 56(4):605-13. PubMed ID: 12666586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of a Haemophilus influenzae B (Hib)-hepatitis B vaccine with a modified process hepatitis B component administered with concomitant pneumococcal conjugate vaccine to infants.
    Lee AW; Vesikari T; Gilbert CL; Klopfer SO; Schödel FP; Bhuyan PK
    Vaccine; 2011 Oct; 29(45):7942-8. PubMed ID: 21875633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Host factors related to poor immunogenicity of hepatitis B vaccine in adults. Another reason to immunize early.
    Margolis HS; Presson AC
    JAMA; 1993 Dec 22-29; 270(24):2971-2. PubMed ID: 8254860
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunological response to hepatitis B vaccine in polytransfused thalassemic patients.
    Alavian SM; Tabatabaei SV
    Pediatr Hematol Oncol; 2010 May; 27(4):324-5; author reply 326-7. PubMed ID: 20426525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age.
    Heyward WL; Kyle M; Blumenau J; Davis M; Reisinger K; Kabongo ML; Bennett S; Janssen RS; Namini H; Martin JT
    Vaccine; 2013 Nov; 31(46):5300-5. PubMed ID: 23727002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New vaccination strategies for low- and non-responders to hepatitis B vaccine.
    Rendi-Wagner P; Wiedermann G; Stemberger H; Kollaritsch H
    Wien Klin Wochenschr; 2002 Mar; 114(5-6):175-80. PubMed ID: 12238305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prevention and vaccination against hepatitis].
    de la Briére A; Berenguerb M; Destombesa C
    Soins; 2013 Nov; (780):29-31. PubMed ID: 24409612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies to ensure delivery of hepatitis B vaccine to injecting drug users.
    Heptonstall J
    Commun Dis Public Health; 1999 Sep; 2(3):154-6. PubMed ID: 10491865
    [No Abstract]   [Full Text] [Related]  

  • 30. [Evaluation on efficacy of plasma-derived hepatitis B vaccine and persistence of protective level after vaccination].
    Wang S; Wu C; Li Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 1994 Jun; 15(3):154-7. PubMed ID: 7834691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seroconversion rate after postnatal immunoprophylaxis for exposed infants in prevention of hepatitis B vertical transmission.
    Ramanan PV; Premkumar S; Khanna P; Sahni L
    J Trop Pediatr; 2011 Oct; 57(5):399. PubMed ID: 21212130
    [No Abstract]   [Full Text] [Related]  

  • 32. Low response to hepatitis B vaccine in health care workers and medical students in Lisbon, Portugal.
    Marinho RT; Ramalho F; Velosa J
    Hepatology; 1998 Oct; 28(4):1166. PubMed ID: 9841230
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine.
    Rendi-Wagner P; Shouval D; Genton B; Lurie Y; Rümke H; Boland G; Cerny A; Heim M; Bach D; Schroeder M; Kollaritsch H
    Vaccine; 2006 Apr; 24(15):2781-9. PubMed ID: 16455169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules.
    Wilson JN; Nokes DJ; Medley GF; Shouval D
    Vaccine; 2007 May; 25(18):3705-12. PubMed ID: 17306427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of hepatitis B, tetanus, hepatitis A, human immunodeficiency virus and feasibility of vaccine delivery among injecting drug users in Bangkok, Thailand, 2003-2005.
    Sunthornchart S; Linkins RW; Natephisarnwanish V; Levine WC; Maneesinthu K; Lolekha R; Tappero JW; Trirat N; Muktier S; Chancharastong P; Fox K; Donchalermpak S; Vitek C; Supawitkul S
    Addiction; 2008 Oct; 103(10):1687-95. PubMed ID: 18705685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changing serological status and low vaccination-induced protection rates against hepatitis B characterize chronic hepatitis C virus-infected injecting drug users in Greece: need for immunization policy.
    Elefsiniotis IS; Pantazis KD; Ketikoglou ID; Koutsounas SI; Tsianos EV
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1227-31. PubMed ID: 17033445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of two paediatric doses of monovalent hepatitis B or combined hepatitis A and B vaccine in 8-10-year-old children.
    Duval B; Gîlca V; Boulianne N; Deceuninck G; Rochette L; De Serres G
    Vaccine; 2005 Jul; 23(31):4082-7. PubMed ID: 15963363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic.
    Ramasamy P; Lintzeris N; Sutton Y; Taylor H; Day CA; Haber PS
    Addiction; 2010 Feb; 105(2):329-34. PubMed ID: 20078489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The causes for hyporeactiveness of vaccination against hepatitis B and the strategies to resolve the situations].
    Cheng SC; Lo CH
    Zhonghua Yu Fang Yi Xue Za Zhi; 1993 Mar; 27(2):108-10. PubMed ID: 8354106
    [No Abstract]   [Full Text] [Related]  

  • 40. Hepatitis B vaccination.
    Gray J; Hewett N; Hiley A
    Br J Gen Pract; 2004 Sep; 54(506):704. PubMed ID: 15353063
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.